MarkJasonRoschewskiMD
Hematology • Germantown, MDHematologic Oncology
Staff Clinician National Cancer Institute
Dr. Roschewski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9000 Rockville Pike
Room 4N/115
Germantown, MD 20874Phone+1 301-451-9021
Education & Training
National Capital ConsortiumFellowship, Hematology and Medical Oncology, 2006 - 2009
Dwight David Eisenhower Army Medical CenterResidency, Internal Medicine, 2001 - 2004
University of Nebraska College of MedicineClass of 2001
Certifications & Licensure
NE State Medical License 2006 - 2026
SD State Medical License 1900 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies Start of enrollment: 2009 Mar 05
- Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) Start of enrollment: 2010 Apr 22
- A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma Start of enrollment: 2010 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsPhase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.Mark Roschewski, Manish R Patel, Patrick M Reagan, Nakhle S Saba, Graham P Collins
Clinical Cancer Research. 2023-09-01 - 122 citationsRacial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.Ola Landgren, B I Graubard, Jerry A. Katzmann, Robert A. Kyle, I Ahmadizadeh
Leukemia. 2014-07-01 - 18 citationsDiffuse large B cell lymphoma: molecular targeted therapyMark Roschewski, Kieron Dunleavy, Wyndham H. Wilson
International Journal of Hematology. 2012-10-20
Journal Articles
- End-of-Treatment and Serial PET Imaging Has Prognostic Value and Clinical Utility in Primary Mediastinal B-cell Lymphoma Following Dose-Adjusted EPOCH-R - Response to ...Mark Roschewski, Wyndham H Wilson, Christopher Melani, Haematologica
Abstracts/Posters
- Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell LymphomasMark Roschewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...Mark Roschewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RRMark Roschewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- No Maintenance Required: Arguing in Favor of Observation after Frontline Therapy in Follicular...ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
- Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvemen...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
CAR T-cell Win Streak Stopped by Negative Trial in Aggressive LBCLDecember 14th, 2021- BTK Inhibition May Counter Hyperinflammatory Response Associated with Severe COVID-19July 28th, 2020
- New EPOCH for Adult Patients with Burkitt LymphomaJune 17th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
